Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STRO 
Sutro Biopharma (STRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: STRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.11
1 Year Target Price $3.11
| 4 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.15% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.91M USD | Price to earnings Ratio - | 1Y Target Price 3.11 |
Price to earnings Ratio - | 1Y Target Price 3.11 | ||
Volume (30-day avg) 10 | Beta 1.67 | 52 Weeks Range 0.52 - 4.80 | Updated Date 08/29/2025 |
52 Weeks Range 0.52 - 4.80 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.41 | Actual -0.14 |
Profitability
Profit Margin -199.76% | Operating Margin (TTM) 23.65% |
Management Effectiveness
Return on Assets (TTM) -27.54% | Return on Equity (TTM) -347.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -109631202 | Price to Sales(TTM) 0.73 |
Enterprise Value -109631202 | Price to Sales(TTM) 0.73 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 0.41 | Shares Outstanding 84774200 | Shares Floating 67149626 |
Shares Outstanding 84774200 | Shares Floating 67149626 | ||
Percent Insiders 4.59 | Percent Institutions 62.94 |
Upturn AI SWOT
Sutro Biopharma
Company Overview
History and Background
Sutro Biopharma, founded in 2003, is a clinical-stage drug discovery, development and manufacturing company focused on oncology and autoimmune diseases. It develops cancer therapies using its XpressCF+ and integrated cell-free protein synthesis platform.
Core Business Areas
- Drug Discovery and Development: Focuses on developing antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine derivatives using its proprietary XpressCF+ platform.
- Manufacturing: Sutro has in-house manufacturing capabilities for its clinical trial materials and is expanding for potential commercial supply.
- Partnerships: Collaborates with pharmaceutical companies to discover and develop novel therapies.
Leadership and Structure
The company is led by CEO Bill Newell. The organizational structure consists of research, development, manufacturing, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- STRO-002: STRO-002 is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FolRu03b1) for ovarian cancer and endometrial cancer. Clinical trials are ongoing. Competitors include ImmunoGen(IMGN) with Elahere, and Mersana Therapeutics (MRSN).
- STRO-001: STRO-001 is an antibody-drug conjugate (ADC) targeting CD74 for B-cell malignancies. Clinical trials were halted. Competitors include other CD74 targeted therapies.
- CC-99712: CC-99712 is an ADC being developed in collaboration with Bristol Myers Squibb (BMY) targeting BCMA. Competitors include Blenrep from GSK (GSK).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, driven by innovation and regulatory hurdles. The market for ADCs is expanding rapidly due to their targeted delivery and efficacy.
Positioning
Sutro Biopharma is a player in the ADC space, leveraging its cell-free protein synthesis platform to create novel therapeutics. It seeks competitive advantage through the novelty of the XpressCF platform.
Total Addressable Market (TAM)
The ADC market is expected to reach billions of dollars. Sutro Biopharma is positioned to capture a segment of this market with its pipeline, however currently does not have revenue generating products.
Upturn SWOT Analysis
Strengths
- Proprietary XpressCF+ platform
- In-house manufacturing capabilities
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- No currently marketed products
- Dependence on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Halting of certain drug programs
Opportunities
- Expanding the application of XpressCF+ platform to new targets and therapeutic areas
- Potential for breakthrough therapies in oncology
- Further collaborations and licensing agreements
- Advancing pipeline candidates through clinical development
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- IMGN
- MRSN
- BMY
- GSK
Competitive Landscape
Sutro Biopharma competes in the crowded biopharmaceutical space. Sutro's advantage is its cell-free protein synthesis, however, larger companies can develop more products and have much larger R&D budgets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires up-to-date data. Please consult financial news sites for latest values.
Future Projections: Future projections require up-to-date data. Please consult financial news sites for latest values.
Recent Initiatives: Recent strategic initiatives include advancing STRO-002 through clinical trials and expanding partnerships. Focus is on key pipeline assets.
Summary
Sutro Biopharma is a clinical-stage biopharmaceutical company with a promising XpressCF+ platform for developing ADCs. Its main challenge is obtaining clinical trial success and generating revenue, as well as having enough funding. The company has potential for growth through partnerships and expanding its pipeline. However, competition and regulatory hurdles pose significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sutro Biopharma
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-09-27 | CEO & Director Ms. Jane Chung R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 244 | Website https://www.sutrobio.com |
Full time employees 244 | Website https://www.sutrobio.com | ||
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.